Tamiflu: A poster child for transparency in clinical trials?
Thursday 10 April saw the publication of the Cochrane systematic review on oseltamivir and zanamivir, or Tamiflu (Roche) and Relenza (GlaxoSmithKline) to give… Read more »
Thursday 10 April saw the publication of the Cochrane systematic review on oseltamivir and zanamivir, or Tamiflu (Roche) and Relenza (GlaxoSmithKline) to give… Read more »
‘A wise man learns by the mistakes of others, a fool by his own’ Latin proverb This is especially true in evidence-based medicine. While it is often the… Read more »
“It is difficult to make informed decisions if publication bias and selective reporting are present” World Health Organization For years, researchers have… Read more »
Perceptions of the value of peer-reviewed case reports have shifted significantly in recent years, with increasing interest in making them more widely… Read more »
Making the results of all clinical trials accessible to researchers, clinicians and the public not only promotes transparency in clinical research, it also… Read more »